# Adimanebart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/adimanebart

> The next catalyst for adimanebart, sponsored by ARGENX SE (ARGX), is its topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for adimanebart?

The next catalyst for adimanebart, sponsored by ARGENX SE (ARGX), is its topline data readout, 2H 2027. Press release filed with the SEC (EX-99): "Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027. 1.3.5 adimanebart (ARGX-119) Development adimanebart is a humanized agonist monoclonal antibody that specifically targets and activates MuSK to promote maturation and stabilization of the NMJ, with planned development across severe neuromuscular diseases including CMS, ALS, and SMA." [Calendar and source filings](https://sec-api.dev/pdufa/adimanebart)

Source: Press release filed with the SEC (EX-99), accession 0001697862-26-000030, https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm (retrieved 2026-11-12). Last confirmed 2026-03-19. Cite: https://sec-api.dev/pdufa/adimanebart#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | adimanebart |
| Codes | ARGX-119 |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-02-27, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "(8) its plans to develop ARGX-119, including: (a) Phase 1b proof-of-concept study in CMS, with topline results expected in second half of 2025" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "•Phase 1b proof-of-concept study ongoing in CMS; topline results expected in second half of 2025" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "•Phase 1b proof-of-concept study ongoing in CMS; topline results expected in second half of 2025" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected in 2H 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "2026, respectively; its plans to develop ARGX-119, including: (1) proof-of-concept study in CMS, with topline results expected in second half of 2025; (2) Phase 2a proof-of-concept study in ALS, with topline results expected in first half of 2026; and (3) SMA proof-of-concept study, expected to start in 2025; the expected start and timeline of Phase 1 studies of ARGX-109 in second half of 2025 and ARGX-213 and ARGX-121 in first half of 2026; the expected change from Mr. deBethizy to Ms. Cespedes as the Chair of the Remuneration" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-05-08, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "(b) Phase 2a proof-of-concept study in ALS, with topline results expected in first half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-03-19, last confirmed 2026-03-19.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027. 1.3.5 adimanebart (ARGX-119) Development adimanebart is a humanized agonist monoclonal antibody that specifically targets and activates MuSK to promote maturation and stabilization of the NMJ, with planned development across severe neuromuscular diseases including CMS, ALS, and SMA." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/adimanebart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Adimanebart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/adimanebart

```bibtex
@misc{secapidev_pdufa_adimanebart_20261116,
  title        = {Adimanebart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/adimanebart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_adimanebart_20261116","title":"Adimanebart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/adimanebart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
